DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1418 Valderramos SG, Fidock DA. Transporters involved in resistance
to antimalarial drugs. Trends Pharmacol Sci, 2006, 27:
594–601.
Vale N, Moreira R, Gomes P. Primaquine revisited six decades
after its discovery. Eur J Med Chem, 2009, 44:937–953.
Vinetz JM, Li J, McCutchan TF, Kaslow DC. Plasmodium malariae
infection in an asymptomatic 74-year-old Greek woman
with splenomegaly. N Engl J Med, 1998, 338: 367–371.
Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R.
Antimalarial drugs and pregnancy: safety, pharmacokinetics,
and pharmacovigilance. Lancet Infect Dis, 2007, 7:136–144.
Wells TN, Alonso PL, Gutteridge WE. New medicines to
improve control and contribute to the eradication of malaria.
Nat Rev Drug Discov, 2009, 8:879–891.
World Health Organization. World Malaria Report, 2009. Available
at: http://www.who.int/malaria/world_malaria_report_2009/en/
index.html. Accessed January 12, 2010.
White NJ. Antimalarial drug resistance. J Clin Invest, 2004,
113:1084–1092.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
White NJ. Qinghaosu (artemisinin): The price of success.
Science, 2008, 320:330–334.
Wiesner J, Jomaa H. Isoprenoid biosynthesis of the apicoplast
as drug target. Curr Drug Targets, 2007, 8:3–13.
Wiesner J, Reichenberg A, Heinrich S, et al. The plastid-like
organelle of apicomplexan parasites as drug target. Curr
Pharm Des, 2008, 14:855–871.
Winzeler EA. Malaria research in the post-genomic era. Nature,
2008, 455:751–756.
Yeshiwondim AK, Tekle AH, Dengela DO, et al. Therapeutic
efficacy of chloroquine and chloroquine plus primaquine for
the treatment of Plasmodium vivax in Ethiopia. Acta Trop,
2010, 113:105–113.
Zhang K, Rathod PK. Divergent regulation of dihydrofolate
reductase between malaria parasite and human host. Science,
2002, 296:545–547.